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Summary. Background: The role of inherited prothrombotic
conditions, including factorVLeiden (FVG1691A), prothrom-
bin G20210A, and the methylenetetrahydrofolate reductase
(MTHFR) C677T genotype, in the pathogenesis of ischemic
stroke is notwell established. The eﬀects of these factorsmay be
potentiated by the use of oral contraceptives, analogous to
observations in venous thrombosis. Methods: Patients (n ¼
193) were women aged 20–49 years with ischemic stroke.
Controls (n ¼ 767) were women without arterial thrombosis
stratiﬁed for age, calendar year of the index event, and
residence. The relative risk of ischemic stroke was estimated
with unconditional logistic regression, adjusted for stratiﬁcation
variables. Findings: Factor V Leiden and MTHFR 677TT
were more common in patients than in controls [odds ratio
(OR): 1.8; 95% conﬁdence interval (CI): 0.9–3.6 respectively
OR: 1.5; 95% CI: 0.9–2.6]. The frequency of prothrombin
G20210A was similar in cases and controls. Carriers of FV
Leiden using oral contraceptives had a 11.2-fold (95%CI: 4.3–
29.0) higher risk of ischemic stroke than women without either
risk factor. Women with MTHFR 677TT using oral contra-
ceptives had a 5.4-fold (95% CI: 2.4–12.0) higher risk than
women without these risk factors. Interpretation: These data
suggest that carriers of FV Leiden orMTHFR 677TT who use
oral contraceptives have an increased risk of ischemic stroke.
When these ﬁndings are conﬁrmed, a cost-eﬀectiveness analysis
should indicate whether ischemic stroke could be prevented
with genetic testing before the start of oral contraceptives.
Keywords: blood coagulation, contraceptives, factor V, meth-
ylenetetrahydrofolate reductase, prothrombin, stroke.
Introduction
The factor (F)V Leiden (G1691A) and prothrombin G20210A
mutations are risk factors for venous thrombosis [1,2]. The risk
of venous thrombosis related with FV Leiden or prothrombin
G20210A is enhanced by the use of oral contraceptives [3,4].
The association of these mutations with arterial thrombosis
such as ischemic stroke has not been well established, but seems
to be much weaker [5,6], possibly with the exception of female
smokers [7]. Another frequent genetic factor is the methylene-
tetrahydrofolate reductase (MTHFR) 677T variant. The
homozygous form, MTHFR 677TT was found to increase
the risk of arterial thrombosis in a meta-analysis [5], but not in
a recent large study [8].
The use of oral contraceptives approximately doubles the
risk of ischemic stroke [9,10]. The strength of this relationship
depends on smoking and hypertension [9,10], and probably
other, still unknown factors. A recent, small study suggests that
prothrombin G20210A increases the risk of ischemic stroke
related with oral contraceptives [11].
In carriers of FV Leiden, inactivation of FVa by activated
protein C (APC) is greatly impaired [1], which results in a
prothrombotic state. The prothrombin G20210A mutation
increases the risk of venous thrombosis via elevation of pro-
thrombin levels [2]. MTHFR is an enzyme involved in the
metabolism of homocysteine. Plasma level of homocysteine is
increased in carriers of the MTHFR 677T allele [12,13].
Increasing homocysteine levels are a risk factor for stroke [14–
16], possibly due to endothelial dysfunction at several levels,
including depression of protein C activation [16]. Interestingly,
estrogens also increase the resistance to APC, particularly oral
contraceptives containing third generation progestogens (des-
ogestrel, gestodene) [17,18].
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The aim of this study was ﬁrstly to investigate whether FV
Leiden, prothrombin G20210A, and MTHFR 677TT are
associated with the risk of ischemic stroke, and secondly
whether the association is affected by the use of oral
contraceptives and smoking.
Patients and methods
Study design
The Risk of Arterial Thrombosis in relation to Oral Contra-
ceptives (RATIO) study is a multicenter, population-based
case–control study. The study consists of three substudies on
stroke, myocardial infarction, and peripheral arterial disease.
The ﬁrst phase evaluated the risk of arterial thrombosis related
to the use of oral contraceptives (1990–1995) [9,19,20]. In the
second phase, blood samples were drawn or buccal swabs
collected for the determination of prothrombotic conditions
(1998–2002). The study was approved by the medical ethics
committees of the participating hospitals. All participants gave
informed consent.
Study population
Eligible cases were women aged 18–49 years who were
hospitalized for a ﬁrst ischemic stroke in one of nine
participating Dutch hospitals between 1990 and 1995. Stroke
was diagnosed in all patients based on the medical history,
neurologic examination as well as computed tomography (CT)-
or magnetic resonance imaging (MRI)-scan by experienced
neurologists in the participating centers. Exclusion criteria were
transient ischemic attack (an event lasting <24 h), hemor-
rhagic stroke, cerebral venous sinus thrombosis, carotid artery
dissection, history of cardiovascular or cerebrovascular dis-
eases, terminal illness, aphasia or cognitive impairment
interfering with the questionnaire or not speaking Dutch. Of
the 295 eligible patients admitted during the study period, 203
(69%) patients agreed to participate in the ﬁrst phase of the
study [9]. Further, we approached 59 additional ischemic stroke
patients who presented in the University Medical Center
Utrecht between 1996 and 2001, using the same inclusion and
exclusion criteria. Of 262 eligible patients in the second phase,
six had died, 19 refused to participate and 44 could not be
located. Therefore, 193 patients (74%) were included in the
present study.
A population-based control group was identiﬁed by random
digit dialing between 1990 and 1995 [9]. This group was
frequency matched to the ﬁrst 203 cases for age, residence, and
year of the stroke [9]. Eligible were women aged 18–49 years
without a history of coronary heart disease, cerebrovascular
event or peripheral vascular disease. A questionnaire was sent
to women who were eligible as controls. A total of 925 of 1039
eligible women (response rate 89%) were included as controls
in the RATIO study for the three case groups combined. DNA
was obtained from 767 women (83% of the controls of the ﬁrst
phase).
Data collection and definitions
Patients and controls received a standardized mail question-
naire on use of oral contraceptives, smoking status, alcohol use,
weight, height, physician’s diagnosis and medication use for
hypertension, diabetes mellitus, and hypercholesterolemia.
Color photographs of boxes of all oral contraceptives were
used to help women recall the speciﬁc type of oral contracep-
tives they had used. All questions referred to the time period
preceding the index date, i.e. the date of stroke in patients and
the mid-year of the same year in controls. Current use of oral
contraceptives was deﬁned as use of a contraceptive pill within
1 month before the index date. Non-use was deﬁned as
previous use or never use. Smoking was categorized into
current, former, and never smoking. Current smoking was
deﬁned as having smoked at least one cigarette a day in the year
before the index date. Alcohol use before the index date was
categorized into never, 1–15 drinks a week, and more than 15
drinks a week, in the year before the index date. At the time of
blood collection, we were able to conﬁrm the data on
hypertension, diabetes, and hypercholesterolemia. Blood pres-
sure was measured twice in a supine position after 5 min rest
and averaged. A women was classiﬁed as hypertensive when
using antihypertensive medication, having a systolic blood
pressure of 160 mmHg or higher, or a diastolic blood pressure
of 95 mmHg or higher at the time of venepuncture.
Isolated DNA from whole venous blood or mouth swaps
was analyzed for FV Leiden, prothrombin G20210A, and
the MTHFR genotype with a standard polymerase chain
reaction (PCR) [7]. The technician who performed DNA
analyses was blinded to whether a sample was from a
patient or a control.
Statistical analysis
The relative risk of ischemic stroke associated with FV Leiden,
prothrombin G20210A or MTHFR 677TT was assessed as an
odds ratio (OR) with 95% conﬁdence intervals (CI) using
unconditional logistic regression. Adjustments were made for
the stratiﬁcation variables: age, calendar year of the index
event, and residence. The additional cases were assigned the
highest index year of patients from the ﬁrst study phase with
whom the controls were matched. The effect of a combination
of risk factors, i.e. a coagulation defect and use of oral
contraceptives was analyzed by computing ORs in subjects
with either one or both of these risk factors, compared to those
with neither risk factor, in a model adjusting for the stratiﬁ-
cation variables.
Results
Table 1 summarizes the characteristics of the 193 cases with
ischemic stroke and 767 controls. The age of the patients varied
between 20 and 49 years. Control women were between 18 and
53 years. The characteristics of the ischemic stroke cases were
consistent with previous studies in that hypertension, diabetes
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mellitus, hypercholesterolemia, use of oral contraceptives, and
smoking were more frequent than in the controls (Table 1).
The use of oral contraceptives was associated with a 3.1-fold
(95% CI: 2.0–4.6) increased risk of ischemic stroke. Cases
reported less alcohol use than controls.
As shown in Table 2, FV Leiden and MTHFR 677TT were
more common in patients with ischemic stroke than in controls.
FV Leiden increased the risk of ischemic stroke 1.8-fold (95%
CI: 0.9–3.6). The OR for ischemic stroke associated with
MTHFR 677TT was 1.5 (95% CI: 0.9–2.6). Although
confounding is essentially not possible for genetic risk factors,
we adjusted for other risk factors for stroke, such as:
hypertension, diabetes mellitus, hypercholesterolemia, smo-
king, use of alcohol, and oral contraceptives. This did not lead
to an attenuation of the observed associations (data not
shown). The frequency of prothrombin G20210A was similar
in patients and controls (OR: 1.0; 95% CI: 0.3–3.0).
In women who did not use oral contraceptives, FV Leiden
was not associated with an increased risk (Table 3). In the
absence of FV Leiden, we found a 2.6-fold (95% CI: 1.7–4.0)
increased risk of ischemic stroke for oral contraceptives users.
Carriers of FVLeiden who used oral contraceptives had a 11.2-
fold increased risk of ischemic stroke (95%CI: 4.3–29.0), which
did not change when adjustments were made for other risk
factors mentioned above. Table 3 further shows the effects of
FV Leiden and smoking on the risk of ischemic stroke. The
highest relative risk was found in current smokers with FV
Leiden (OR: 6.3; 95% CI: 1.3–31.1) when compared with non-
smoking non-carriers.
The combined effects ofMTHFR 677TT and the use of oral
contraceptives are shown in Table 4. There was no increased
risk of ischemic stroke associated with MTHFR 677TT in
women who did not use oral contraceptives. Oral contracep-
tives increased the risk of ischemic stroke in the absence of
MTHFR 677TT (OR: 2.8; 95% CI: 1.8–4.3), and apparently
more so in the presence of MTHFR 677TT (OR: 5.4; 95% CI:
2.4–12.0). These observations were not affected by additional
adjustments for the above-mentioned risk factors (data not
shown). The combined effects of smoking andMTHFR677TT
did not exceed the separate effects (Table 4). As there were only
ﬁve patients who carried the prothrombin G20210A mutation,
we could not study the combined effects with oral contracep-
tives.
Table 1 Characteristics of the study population*
Patients (N ¼ 193) Controls (N ¼ 767)
Age 38.6 (8.0) 39.7 (7.7)
Caucasian ethnicity 95.9 (185) 94.3 (723)
Hypertension 32.1 (62) 6.1 (47)
Diabetes mellitus 4.1 (8) 1.3 (10)
Hypercholesterolemia 7.8 (15) 2.9 (22)
Oral contraceptives use 52.3 (101) 35.7 (272)
Smoking, current 34.7 (67) 32.2 (247)
Former 44.0 (85) 34.8 (267)
Never 21.2 (41) 32.3 (248)
Alcohol use, never 46.6 (90) 29.6 (227)
0–15 drinks a week 44.6 (86) 65.2 (500)
>15 drinks a week 1.0 (2) 4.2 (32)
*Values are mean (SD) or proportions (numbers).
Age at index date.
Data were missing on ethnicity in one patient and in four controls, on
diabetes mellitus in three controls, on hypercholesterolemia in ﬁve
controls, on oral contraceptive use in six controls, on smoking in ﬁve
controls, and on alcohol use in 15 patient and eight controls.
Table 2 Association of factor V Leiden, prothrombin G20210A, and
methylenetetrahydrofolate reductase (MTHFR) 677TT with ischemic
stroke*
Patients Controls Odds ratio
Factor V Leiden 7.8% (14/179) 5.5% (42/763) 1.8 (0.9–3.6)
Prothrombin G20210A 2.7% (5/188) 2.4% (18/763) 1.0 (0.3–3.0)
MTHFR 677TT 13.5% (26/193) 9.0% (69/764) 1.5 (0.9–2.6)
*Values are number of patients/controls and odds ratios with 95%
conﬁdence interval adjusted for age at index date, index year, and
residence.
Data were missing on factor V Leiden in four controls and 14 cases, on
prothrombin G20210A in four controls and ﬁve patients, and on
MTHFR in three controls.
Table 3 Association of factor V Leiden (FVL) and ischemic stroke: eﬀects
of oral contraceptives and smoking*
FVL absent FVL present
No oral contraceptives 83/463 2/24
1 (reference) 0.4 (0.1–1.9)
Oral contraceptives 82/254 12/16
2.6 (1.7–4.0) 11.2 (4.3–29.0)
Never or former smokers 109/477 10/35
1 (reference) 1.6 (0.7–3.6)
Current smokers 56/242 4/5
1.0 (0.7–1.5) 6.3 (1.3–31.1)
*Values are number of patients/controls and odds ratios with 95%
conﬁdence interval adjusted for age at index date, index year, and
residence.
Data were missing on FVL in four controls and 14 cases, on oral
contraceptive use in six controls and on smoking in ﬁve controls.
Table 4 Association of methylenetetrahydrofolate reductase (MTHFR)
C677T and ischemic stroke: eﬀects of oral contraceptives and smoking*
CC or CT TT
No oral contraceptives 82/441 10/46
1 (reference) 1.1 (0.5–2.4)
Oral contraceptives 85/248 16/23
2.8 (1.8–4.3) 5.4 (2.4–12.0)
Never or former smokers 110/472 16/41
1 (reference) 1.4 (0.7–2.8)
Current smokers 57/219 10/28
1.0 (0.7–1.5) 1.7 (0.7–4.1)
*Values are number of patients/controls and odds ratios with 95%
conﬁdence interval adjusted for age at index date, index year, and
residence.
Data were missing on MTHFR in three controls, on oral contraceptive
use in six controls and on smoking in ﬁve controls.
CC, CT and TT denote the MTHFR C677T genotypes.
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Discussion
In this population-based, case–control study of women of
reproductive age, we found that FV Leiden and MTHFR
677TT increased the risk of ischemic stroke. Furthermore, we
found a high relative risk of ischemic stroke for both FVLeiden
and MTHFR 677TT in combination with the use of oral
contraceptives. In addition, smoking carriers of FV Leiden had
an increased risk of ischemic stroke relative to women without
either risk factor.
In the interpretation of these ﬁndings, a possible limitation is
that we only studied women who survived an ischemic stroke.
However, mortality after stroke in young women is low [21].
Indeed, of the eligible patients in this study, mortality was 6%
(n ¼ 18) before inclusion in the ﬁrst phase [9], and 2% (n ¼ 6)
before the second wave. If the genetic factors of interest would
have been associated with case-fatality, selection of surviving
ischemic stroke patients would have led to an underestimation
of the true effect. Secondly, we did not collect data on the
subtype of ischemic stroke. The proportion of patients with a
cardioembolic stroke is likely to be low, because history of
cardiovascular disease was used as an exclusion criterion.
Thirdly, we included hospitalized patients only. However, as a
stroke is uncommon before the age of 50 years [22], it is
unlikely that patients of this age will not be referred to the
hospital and thus not included in this study. The control group
was population-based with a high response rate, and these
women were not informed about the determinants of this
study. It is therefore not likely that the willingness to participate
was related to determinants under study, such as the use of oral
contraceptives. All laboratory analyses were performed with-
out knowledge of case–control status. Inaccurate information
on oral contraceptive use is unlikely as we used color
photographs of pillboxes to determine exposure to oral
contraceptives. Based on these considerations, we think it is
unlikely that our ﬁndings are biased.
An advantage of this study is its large size, for a disease that
is infrequent in young women. As the use of oral contraceptives
in the Netherlands is high (approximately 35%), we were able
to study joint effects with FV Leiden and MTHFR 677TT.
Further, we included hospitalized patients only and excluded
transient ischemic attacks. As diagnostic procedures in these
young women were extensive, it is unlikely that incorrect
diagnosis of stroke has played an important role. We did not
explore subtypes of ischemic stroke, as this study aimed to
investigate the implications for public health of oral contra-
ceptives and prothrombotic mutations.
The risk of arterial thrombosis associated with FV Leiden,
prothrombin G20210A or MTHFR 677TT may dilute with
aging, and seems to be higher in women than in men [5,6,23–
25]. Compared with previous investigations, our study popu-
lation was relatively young and consisted entirely of women.
This may explain that we detected higher ORs for ischemic
stroke than most other studies [5,6,8,23]. The relatively high
proportion of oral contraceptives users could also explain
differences across studies.
Our study suggests a high relative risk for combinations
of FV Leiden as well as MTHFR 677TT with oral
contraceptives in the risk of ischemic stroke. Our ﬁndings
should be replicated in other studies and followed by a
cost-effectiveness analysis before large-scale genetic screening
is considered.
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